Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 11855.154 | 0.9167 | 0.7414 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 11855.154 | 0.9275 | 0.7742 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 11855.154 | 0.9428 | 0.8209 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 11855.154 | 0.9114 | 0.7254 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 11855.154 | 0.8927 | 0.6693 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 11855.154 | 0.8427 | 0.5230 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 11855.154 | 0.7400 | 0.2383 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 11855.154 | 0.6510 | 0.0100 | 0.6282 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 11855.154 | 0.5527 | -0.2219 | 0.6282 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12305.167 | 0.9762 | 0.9834 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12305.167 | 0.9171 | 0.9409 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12305.167 | 1.0551 | 1.0375 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12305.167 | 1.0609 | 1.0415 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12305.167 | 0.7135 | 0.7789 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12305.167 | 0.6503 | 0.7225 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12305.167 | 0.5151 | 0.5887 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12305.167 | 0.1767 | 0.0960 | 2.8814 | |
| BT-549 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12305.167 | 0.0037 | -0.7128 | 2.8814 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000256 | uM | 10473.142 | 1.0565 | 1.1042 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00128 | uM | 10473.142 | 1.0035 | 1.0065 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0064 | uM | 10473.142 | 1.0619 | 1.1142 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.032 | uM | 10473.142 | 1.0732 | 1.1350 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.16 | uM | 10473.142 | 0.9704 | 0.9452 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.8 | uM | 10473.142 | 1.0245 | 1.0453 | 1.0815 | |
| CAMA-1 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 4 | uM | 10473.142 | 0.8433 | 0.7083 | 1.0815 |